三阴性乳腺癌治疗进展  

Advances in treatment of triple negative breast cancer

作　　者：张继博[1] 史业辉[1] 贾勇圣[1] 佟仲生[1] 

机构地区：[1]天津医科大学肿瘤医院乳腺肿瘤内科国家肿瘤临床研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心,天津300060

出　　处：《肿瘤》2017年第7期788-794,共7页Tumor

基　　金：国家自然科学基金资助项目(编号:81302080);国家科技支撑计划资助项目(编号:2015BAI12B15)~~

摘　　要：乳腺癌是全世界最常见的一种女性恶性肿瘤。三阴性乳腺癌是指雌激素受体、孕激素受体和人表皮生长因子受体2的表达均为阴性的乳腺癌,约占所有乳腺癌病理类型的15%~20%。三阴性乳腺癌的预后差、复发转移率高、死亡率高,已成为近年来乳腺癌研究和关注的焦点。目前针对乳腺癌的治疗手段包括手术治疗、新辅助化疗、辅助化疗、内分泌治疗和靶向治疗等。由于三阴性乳腺癌患者缺少雌激素受体、孕激素受体和人表皮生长因子受体2的表达,因此患者无法从针对乳腺癌的内分泌治疗及抗人表皮生长因子受体2的靶向治疗中获益。化疗是目前较推荐的三阴性乳腺癌治疗方法。许多化疗方案及新型的化疗药物也正在探索之中。本文对三阴性乳腺癌的化疗、内分泌治疗、靶向治疗和免疫治疗的研究进展进行综述。Breast cancer is the most common malignant tumor in females in the world.The characteristics of triple-negative breast cancer （TNBC） are defined as estrogen receptor （ER）-negative,progesterone receptor （PR）-negative and human epidermal growth factor receptor 2（HER2）-negative.TNBC accounts for about 15%-20% in all the pathological types of breast cancer.With poor prognosis,high recurrence rate and high mortality rate,TNBC has become the focus of the research recently.At present,the treatment methods of breast cancer include surgery,neoadjuvant chemotherapy,adjuvant chemotherapy,endocrine therapy and targeted therapy,etc.Due to the lack of ER,PR and HER2 expressions,patients can not benefit from the endocrine therapy and anti-HER2 targeted therapy.Chemotherapy is currently recommended for the treatment of TNBC.Many chemotherapeutic regimens and new drugs are being explored.This paper reviews the progress in chemotherapy,endocrine therapy,targeted therapy and immunotherapy of TNBC.

关 键 词：乳腺肿瘤 三阴性乳腺癌 新辅助化疗 辅助化疗 靶向治疗 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]